DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.
Takeda will contribute 1 billion yen (approximately 8 million EUR) over five years to enable DNDi to bring quality diagnosis and treatment to people living with five neglected tropical diseases in endemic countries. The funding will allow DNDi to support mobile health teams to reach people in remote and impoverished areas, and to provide patients with quality and adequate clinical supplies at local healthcare facilities.
“Over a billion people worldwide suffer from neglected tropical diseases such as mycetoma, sleeping sickness, leishmaniasis, Chagas disease, and river blindness,” said Dr Bernard Pécoul, DNDi’s Executive Director. “We are thrilled to start a new chapter in our partnership with Takeda, building on many years of collaboration on R&D in the field of neglected tropical diseases. This multi-year contribution from Takeda will enable DNDi to significantly improve access to life-saving medicines for the most neglected populations living in remote areas of Africa, Latin America and Asia, who often have limited access to basic healthcare.”
DNDi will train local health care providers to diagnose and treat these diseases, and support efforts to ensure that people recognize the symptoms, understand the importance of early diagnosis, and where to seek treatment.
Takeda employees worldwide voted to select DNDi to partner in its Global CSR Program, which aims to improve the long-term health of people through disease prevention in developing and emerging countries.
Photo credit: Graham Crouch-DNDi